Oct 8, 2025
KITS Eyecare (KITS) fell 8% on its preliminary Q3 results, which were strong at 25% Y/Y revenue growth…
… and 5% adj. EBITDA margins, as the operating leverage inherent in KITS’ business model starts to show with scale.
With the stock doubling this year, investors were likely looking for a big beat - feels like a breather rather than a change in the thesis.
About Bullpen: Bullpen Finance Inc. publishes content on Canadian markets and provides paid research coverage of select Canadian issuers. Bullpen is paid in cash by covered issuers, does not accept stock or options, does not hold positions in covered securities, and does not conduct investment banking business. Bullpen and LodeRock Advisors Inc. are affiliated; LodeRock provides investor relations services to issuers, some of whom are covered by Bullpen Research. When a post discusses a covered issuer, a specific disclosure appears at the top of the post. This post is published for general information purposes. It is not personalized investment advice and is not tailored to any individual reader’s circumstances. Bullpen is not a registered investment adviser or dealer. For full disclosures, including analyst certification, jurisdictional statements, and conflict of interest policies, please see our Legal & Disclosures section on our website.
